Quick Dispatch:
Your surpass-cvot tirzepatide An Observational Study of Cardiovascular Outcomes of Tirzepatide vs Glucagon-Like Peptide-1 Receptor Agonists orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your surpass-cvot tirzepatide An Observational Study of Cardiovascular Outcomes of Tirzepatide vs Glucagon-Like Peptide-1 Receptor Agonists ships.
Need Help?
Questions about surpass-cvot tirzepatide An Observational Study of Cardiovascular Outcomes of Tirzepatide vs Glucagon-Like Peptide-1 Receptor Agonists, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for surpass-cvot tirzepatide An Observational Study of Cardiovascular Outcomes of Tirzepatide vs Glucagon-Like Peptide-1 Receptor Agonists in your area.
Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics
24.28
Tirzepatide Demonstrates Cardioprotective Effects in SURPASS-CVOT Trial
24.21
Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis
28.60
SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide
22.91
Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT
26.48
In the SURPASS-CVOT head-to-head trial involving over 13,000 adults with T2D and ASCVD, tirzepatide (Mounjaro) matched dulaglutide in reducing major cardiovascular events (8% lower risk) and significantly cut all-cause mortality by 16%
23.84
Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes
22.94
